Kane gets DispersinB from biotech plants

Kane Biotech (TSX-V:KNE) has confirmed the invention of biotech plants producing DispersinB antibiofilm enzyme, representing a proof of concept for developing bacterial disease-resistant agricultural crops. The Company said DispersinB-expressing plants are resistant to plant pathogens due to their ability to inhibit and disrupt biofilms. In addition, this biotech plant can also be used as a [...]

Kane technology makes two new scientific books

The R&D team at Kane Biotech (TSX-V:KNE) has authored two book chapters reviewing their biofilm research methodology and the antibiofilm-antimicrobial technology development strategy for bacterial infection control in two new scientific books. They are Antimicrobial Peptides: Methods and Protocols (Eds. Andrea Giuliani & Andrea C. Rinaldi) and Biofouling: Types, Impact and Anti-Fouling (Eds. Jun Chan [...]

Australia issues patent for Kane’s DispersinB

Kane Biotech (TSXV:KNE) received patent protection in Australia for its DispersinB anti-biofilm technology, the third country to cover the technology. The patent claims the gene encoding DispersinB enzyme and also the amino acid sequence of the enzyme, as well as method of production, pharmaceutical composition, methods of administration and applications in medical devices. Biofilms develop [...]

Kane Biotech increases size of financing

Kane Biotech (TSX-V:KNE) raised the size of its previously announced private placement to a maximum of 4,335,500 units from 3,846,154 units for total proceeds of  up to $563,615.  Net proceeds will be used for the company’s research and development program, and for working capital, Kane said in a statement. Each unit consists of one common [...]